I. **Length of Authorization**

Coverage will be provided for 12 months and may be renewed.

II. **Dosing Limits**

A. **Quantity Limit (max daily dose) [NDC Unit]:**
   - 200 mg/mL single-dose syringe/autoinjector: 2 syringes/autoinjectors per week for 4 doses, then 1 syringe/autoinjector per week

B. **Max Units (per dose and over time) [HCPCS Unit]:**

   **Systemic Lupus Erythematosus (SLE)**
   - 200 mg weekly

   **Lupus Nephritis**
   - Loading dose: 400 mg weekly for 4 doses
   - Maintenance dose: 200 mg weekly

III. **Initial Approval Criteria**

   - The use of samples and free goods do not qualify as an established clinical response.

   - Patient is at least 18 years of age; **AND**

   **Universal Criteria**

   - Patient must not have an active infection; **AND**
   - Patient has not received a live vaccine within 30 days before starting or concurrently with Benlysta; **AND**
   - Will be used in combination with standard therapy (e.g. anti-malarials, corticosteroids, non-steroidal anti-inflammatory drugs, immunosuppressives); **AND**
   - Patient does not have any of the following exclusion criteria:
Severe active central nervous system lupus
- Individuals who are on other biologics: AND

**Systemic Lupus Erythematosus (SLE) † 1,3,4,9-11,13-16**

- Patient has a confirmed diagnosis of SLE with at least 4 diagnostic features (see list of diagnostic SLE criteria below)* one of which must include a positive autoantibody test (e.g., anti-nuclear antibody [ANA] greater than laboratory reference range and/or anti-double-stranded DNA [anti-dsDNA] greater than 2 fold the laboratory reference range if tested by ELISA): AND
- Patient has failed to respond adequately to at least two (2) standard therapies such as antimalarials, corticosteroids, non-steroidal anti-inflammatory drugs, immunosuppressives (excluding intravenous cyclophosphamide): AND
- Patient has one of the following:
  - Safety of Estrogen in Lupus National Assessment – Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score of 6-12
  - ≥2 British Isles Lupus Assessment Group (BILAG) B organ domain scores

**Lupus Nephritis 1,11,12,18-20**

- Patient has active lupus nephritis Class III, IV, or V as confirmed by renal biopsy: AND
- Patient has a confirmed diagnosis of SLE with at least 4 diagnostic features (see list of diagnostic SLE criteria below)* one of which must include a positive autoantibody test (e.g., anti-nuclear antibody [ANA] greater than laboratory reference range and/or anti-double-stranded DNA [anti-dsDNA] greater than 2 fold the laboratory reference range if tested by ELISA): AND
- Patient has failed to respond adequately to standard therapies including corticosteroids AND either cyclophosphamide or mycophenolate mofetil: AND
- Baseline measurement of one or more of the following: urine protein:creatinine ratio (uPCR), estimated glomerular filtration rate (eGFR), or urine protein

† FDA Approved Indication(s)

<table>
<thead>
<tr>
<th>*Systemic Lupus Erythematosus Diagnostic Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient must have at least 4 out of 11 diagnostic SLE features:</strong></td>
</tr>
<tr>
<td>1.  Malar rash</td>
</tr>
<tr>
<td>2.  Discoid rash</td>
</tr>
<tr>
<td>3.  Photosensitivity</td>
</tr>
<tr>
<td>4.  Oral ulcers</td>
</tr>
<tr>
<td>5.  Nonerosive arthritis (involving 2 or more peripheral joints)</td>
</tr>
<tr>
<td>6.  Pleuritis/pericarditis</td>
</tr>
<tr>
<td>- Pleuritis • history of pleuritic pain or rubbing heard by a physician or evidence of pleural effusion</td>
</tr>
<tr>
<td>- Pericarditis • documented by electrocardiogram or rubbing heard by a physician or evidence of pericardial effusion</td>
</tr>
<tr>
<td>7.  Renal disorder</td>
</tr>
<tr>
<td>- Persistent proteinuria &gt; 0.5 grams/day or &gt; 3+ on urine dipstick</td>
</tr>
</tbody>
</table>
- Cellular casts (red cell, hemoglobin, granular, tubular, or mixed)
- Seizures/psychosis
- Hematologic disorder
  - Hemolytic anemia with reticulocytosis
  - Leukopenia < 4,000/mm³ on ≥ 2 occasions
  - Lymphopenia < 1,500/mm³ on ≥ 2 occasions
  - Thrombocytopenia < 100,000/mm³ in the absence of offending drugs
- Immunologic disorder
  - Presence of anti-Sm or antiphospholipid antibodies
  - Presence of anti-double-stranded DNA [anti-dsDNA] greater than 2 fold the laboratory reference range if tested by ELISA
- Positive anti-nuclear antibody [ANA] greater than laboratory reference range

### IV. Renewal Criteria

Coverage can be renewed based on the following criteria:

- Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. in section III: **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: depression, suicidal thoughts, serious infections, signs or symptoms of progressive multifocal leukoencephalopathy (PML), malignancy, severe hypersensitivity reactions/anaphylaxis, serious infusion reactions, etc.: **AND**

**Systemic Lupus Erythematosus (SLE)**

- Adequate documentation of disease stability and/or improvement as indicated by one or more of the following when compared to pre-treatment baseline:
  - Improvement in the SELENA-SLEDAI score of ≥4 points: **OR**
  - No new BILAG-A organ domain score or 2 new BILAG-B organ domain scores: **OR**
  - No worsening (<0.30-point increase) in Physician's Global Assessment (PGA) score: **OR**
  - Seroconverted (negative) or had a 20% reduction in autoantibody level

**Lupus Nephritis**

- Adequate documentation of disease stability and/or improvement as indicated by one or more of the following when compared to pre-treatment baseline:
  - Urine protein:creatinine ratio (uPCR): **OR**
  - Estimated glomerular filtration rate (eGFR): **OR**
  - Urine protein

### V. Dosage/Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic Lupus Erythematosus (SLE)</td>
<td>200 mg subcutaneously* once weekly</td>
</tr>
<tr>
<td></td>
<td>• If transitioning from intravenous therapy, administer the first subcutaneous dose 1 to 4 weeks after the last IV dose.</td>
</tr>
</tbody>
</table>
Lupus Nephritis

400 mg (two 200 mg injections) subcutaneously* once weekly for 4 doses, then 200 mg once weekly thereafter

- Patient may transition from intravenous therapy to subcutaneous therapy any time after the patient completes the first 2 intravenous doses.
- Administer the first subcutaneous dose 1 to 2 weeks after the last IV dose

*May be self-administered

VI. Billing Code/Availability Information

HCPCS Code:
- J3590 – Unclassified biologic (applicable to the subcutaneous formulation only)
- C9399 – Unclassified drugs or biologicals (Hospital Outpatient Use ONLY)

NDC:
- 200 mg/mL single-dose syringe/autoinjector: 49401-0088-xx

VII. References


Appendix 1 – Covered Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>ICD-10 Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M32.10</td>
<td>Systemic lupus erythematosus organ or system involvement unspecified</td>
</tr>
<tr>
<td>M32.11</td>
<td>Endocarditis in systemic lupus erythematosus</td>
</tr>
</tbody>
</table>
Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Applicable State/US Territory</th>
<th>Contractor</th>
</tr>
</thead>
<tbody>
<tr>
<td>E (1)</td>
<td>CA, HI, NV, AS, GU, CNMI</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>F (2 &amp; 3)</td>
<td>AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>5</td>
<td>KS, NE, IA, MO</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>6</td>
<td>MN, WI, IL</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>H (4 &amp; 7)</td>
<td>LA, AR, MS, TX, OK, CO, NM</td>
<td>Novitas Solutions, Inc.</td>
</tr>
<tr>
<td>8</td>
<td>MI, IN</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>N (9)</td>
<td>FL, PR, VI</td>
<td>First Coast Service Options, Inc.</td>
</tr>
<tr>
<td>J (10)</td>
<td>TN, GA, AL</td>
<td>Palmetto GBA, LLC</td>
</tr>
<tr>
<td>M (11)</td>
<td>NC, SC, WV, VA (excluding below)</td>
<td>Palmetto GBA, LLC</td>
</tr>
<tr>
<td>L (12)</td>
<td>DE, MD, PA, NJ, DC (includes Arlington &amp; Fairfax counties and the city of Alexandria in VA)</td>
<td>Novitas Solutions, Inc.</td>
</tr>
<tr>
<td>K (13 &amp; 14)</td>
<td>NY, CT, MA, RI, VT, ME, NH</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>15</td>
<td>KY, OH</td>
<td>CGS Administrators, LLC</td>
</tr>
</tbody>
</table>